Fate Therapeutics Inc
FATE1.255USD
+0.014+1.21%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
143.83MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Fate Therapeutics Inc Unternehmen
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Unternehmensinformationen
BörsenkürzelFATE
Name des UnternehmensFate Therapeutics Inc
IPO-datumOct 01, 2013
Gegründet am2007
CEODr. Bahram Valamehr, Ph.D.
Anzahl der mitarbeiter181
WertpapierartOrdinary Share
GeschäftsjahresendeOct 01
Addresse12278 Scripps Summit Drive
StadtSAN DIEGO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl92131
Telefon18588751803
Websitehttps://fatetherapeutics.com/
BörsenkürzelFATE
IPO-datumOct 01, 2013
Gegründet am2007
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
80.08K
-70.04%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
67.42K
-79.23%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
80.08K
-70.04%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
67.42K
-79.23%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, May 22
Aktualisiert: Thu, May 22
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Redmile Group, LLC
11.23%
ARK Investment Management LLC
9.00%
The Vanguard Group, Inc.
8.99%
BlackRock Institutional Trust Company, N.A.
7.32%
Schonfeld Strategic Advisors LLC
6.80%
Other
56.66%
Aktionäre
Aktionäre
Anteil
Redmile Group, LLC
11.23%
ARK Investment Management LLC
9.00%
The Vanguard Group, Inc.
8.99%
BlackRock Institutional Trust Company, N.A.
7.32%
Schonfeld Strategic Advisors LLC
6.80%
Other
56.66%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
37.69%
Investment Advisor
25.65%
Hedge Fund
18.92%
Research Firm
6.44%
Venture Capital
3.35%
Individual Investor
1.74%
Private Equity
1.47%
Bank and Trust
0.36%
Pension Fund
0.23%
Other
4.15%
Institutionelle Beteiligung
Aktualisiert: Mon, Mar 3
Aktualisiert: Mon, Mar 3
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
439
113.58M
99.11%
-25.75M
2024Q4
487
105.43M
92.56%
-50.79M
2024Q3
521
119.20M
104.73%
-42.15M
2024Q2
531
125.64M
110.45%
-29.93M
2024Q1
543
126.44M
111.19%
-6.65M
2023Q4
556
99.29M
100.70%
-34.38M
2023Q3
581
100.01M
101.45%
-44.66M
2023Q2
611
113.36M
115.11%
-33.43M
2023Q1
624
117.20M
119.39%
-6.61M
2022Q4
637
109.94M
113.01%
-9.96M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Redmile Group, LLC
12.87M
11.23%
-296.11K
-2.25%
Dec 31, 2024
The Vanguard Group, Inc.
10.33M
9.02%
-47.55K
-0.46%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
8.49M
7.41%
+477.62K
+5.96%
Dec 31, 2024
Citadel Advisors LLC
4.38M
3.82%
+100.18K
+2.34%
Dec 31, 2024
Johnson & Johnson Innovation-JJDC, Inc.
3.38M
2.95%
--
--
Dec 31, 2024
Baker Bros. Advisors LP
3.26M
2.84%
+260.63K
+8.69%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
2.90M
2.53%
+279.36K
+10.67%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Fri, Jun 6
Aktualisiert: Fri, Jun 6
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.66%
WisdomTree BioRevolution Fund
0.65%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Biotechnology ETF
0.01%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.66%
WisdomTree BioRevolution Fund
Anteil0.65%
ProShares Hedge Replication ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
ProShares Ultra Nasdaq Biotechnology
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
Invesco Nasdaq Biotechnology ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
iShares Biotechnology ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
